Senseonics to Assume Global Commercial Management of Eversense CGM System
Agreement Overview: PHC Holdings and Ascensia Diabetes Care have signed a preliminary agreement to transfer the commercial operations of the Eversense Continuous Glucose Monitoring systems to Senseonics Holdings, aiming to streamline operations under one entity.
Transition Details: The transition is expected to be completed by January 1, 2026, with Brian Hansen moving to Senseonics to continue his leadership role, and both companies are implementing measures to ensure minimal disruption for customers and providers during the process.
Trade with 70% Backtested Accuracy
Analyst Views on SENS
About SENS
About the author
Strong Performance of European High Growth Tech Companies, Genmab Reports $3.85 Billion Revenue
- Market Resilience: The pan-European STOXX Europe 600 Index rose by 0.77%, supported by strong economic data and earnings results, indicating a cautious optimism in the market despite mixed performances among major stock indexes.
- Genmab's Innovative Partnership: Genmab's strategic alliance with Anthropic aims to integrate AI into its R&D processes, enhancing the efficiency of its antibody product clinical developments, which is expected to solidify its leading position in oncology.
- LINK Mobility's Recovery Potential: Despite a 40.4% contraction in earnings growth, LINK Mobility Group Holding is projected to achieve an annual earnings growth of 71.1%, significantly surpassing the Norwegian market's expectation of 15%, highlighting its strong recovery potential.
- Sensirion's Technological Leadership: Sensirion Holding AG excels in sensor technology with a 5.9% annual revenue growth and a forecasted 25.8% earnings growth, with innovations in environmental monitoring technology further enhancing its market competitiveness.
Senseonics (SENS) Reports Q4 2025 Revenue of ~$14.2M with 103% New Patient Growth
- Significant Revenue Growth: Senseonics reported preliminary unaudited Q4 2025 revenue of approximately $14.2 million and annual revenue of about $35.2 million, indicating strong market performance, with expectations for 2026 global net revenue to reach $58-$62 million, reflecting a growth of 65% to 76%.
- Innovative Patient Growth: The company achieved a remarkable 103% new patient growth in the U.S. during Q4, marking the largest addition of new patients in its history, primarily driven by effective direct-to-consumer marketing strategies, showcasing the effectiveness of its promotional efforts and enhanced brand influence.
- Gross Margin Expectations: Senseonics anticipates a gross margin of approximately 50% for 2026, which will further enhance its profitability and provide funding support for future investments and expansions, reflecting success in cost control and product pricing strategies.
- Enhanced Financial Transparency: The company plans to release its Q4 and full-year 2025 financial results on March 2, 2026, which will provide more financial details and bolster investor confidence in the company's future development, while also expecting a cash and cash equivalents balance of about $94.3 million as of December 31, 2025.
sensiBel Launches SBM100B Microphone, Delivers Studio-Quality Audio in Compact Form
- Audio Breakthrough: The SBM100B microphone from sensiBel achieves an 80dB signal-to-noise ratio and an acoustic overload point of up to 146dB, delivering studio-quality audio suitable for conferencing and industrial sound detection, significantly enhancing recording flexibility and clarity.
- Technological Innovation: Leveraging optical MEMS core technology, the SBM100B overcomes traditional MEMS microphone limitations by using laser interferometry to detect membrane movement, enabling a wider dynamic range and lower noise floor while maintaining a compact form factor, thus advancing audio technology.
- Convenient Solutions: The AURORA and POLARIS kits connect via USB-C, allowing users to start recording within minutes without soldering or specialized tools, greatly simplifying the design process and enhancing product competitiveness in the market.
- Diverse Applications: The SBM100B is applicable in various scenarios such as video conferencing and spatial audio capture, providing exceptional directionality and high bandwidth to meet the growing market demand, supporting sensiBel's transformation and growth in the audio industry.
Examining Senseonics' Story Following Analyst Adjustments and Product Pipeline Developments
Analyst Adjustments: Senseonics Holdings maintains a fair value of approximately $18.92 per share, with slight adjustments in discount rates and revenue growth expectations reflecting a recalibration rather than a fundamental change in the company's long-term outlook.
Bullish and Bearish Perspectives: TD Cowen remains bullish with a Buy rating despite lowering its price target to $15, while Stifel adopts a more cautious Hold rating with a $9 target, highlighting execution and capital risks as key concerns.
Market Visibility and Listing Changes: Senseonics has been added to the NASDAQ Composite Index and will transfer its primary listing to the Nasdaq Global Select Market in 2025, enhancing its visibility among institutional investors.
Future Growth Projections: The company targets $35 million in global net revenue for 2025, driven by the U.S. rollout of Eversense 365 and a doubling of its patient base, while also executing a reverse stock split to maintain listing compliance.
Senseonics Shares Decline as 2025 Forecast Falls Short of Expectations
Financial Performance: Senseonics Holdings reported Q3 2025 revenue of $8.1M, reflecting nearly 90% year-over-year growth, but set its full-year revenue outlook at $35M, below analyst expectations of $36.3M.
Net Loss and Margins: The company's net loss narrowed by 19% year-over-year to $19.5M, missing consensus estimates, despite cuts to R&D expenses and improved gross margins for its Eversense 365 glucose monitoring devices.
TD Cowen Keeps Buy Rating on Senseonics Holdings, Reduces Price Target to $15
Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.
Strong Performance of European High Growth Tech Companies, Genmab Reports $3.85 Billion Revenue
- Market Resilience: The pan-European STOXX Europe 600 Index rose by 0.77%, supported by strong economic data and earnings results, indicating a cautious optimism in the market despite mixed performances among major stock indexes.
- Genmab's Innovative Partnership: Genmab's strategic alliance with Anthropic aims to integrate AI into its R&D processes, enhancing the efficiency of its antibody product clinical developments, which is expected to solidify its leading position in oncology.
- LINK Mobility's Recovery Potential: Despite a 40.4% contraction in earnings growth, LINK Mobility Group Holding is projected to achieve an annual earnings growth of 71.1%, significantly surpassing the Norwegian market's expectation of 15%, highlighting its strong recovery potential.
- Sensirion's Technological Leadership: Sensirion Holding AG excels in sensor technology with a 5.9% annual revenue growth and a forecasted 25.8% earnings growth, with innovations in environmental monitoring technology further enhancing its market competitiveness.
Senseonics (SENS) Reports Q4 2025 Revenue of ~$14.2M with 103% New Patient Growth
- Significant Revenue Growth: Senseonics reported preliminary unaudited Q4 2025 revenue of approximately $14.2 million and annual revenue of about $35.2 million, indicating strong market performance, with expectations for 2026 global net revenue to reach $58-$62 million, reflecting a growth of 65% to 76%.
- Innovative Patient Growth: The company achieved a remarkable 103% new patient growth in the U.S. during Q4, marking the largest addition of new patients in its history, primarily driven by effective direct-to-consumer marketing strategies, showcasing the effectiveness of its promotional efforts and enhanced brand influence.
- Gross Margin Expectations: Senseonics anticipates a gross margin of approximately 50% for 2026, which will further enhance its profitability and provide funding support for future investments and expansions, reflecting success in cost control and product pricing strategies.
- Enhanced Financial Transparency: The company plans to release its Q4 and full-year 2025 financial results on March 2, 2026, which will provide more financial details and bolster investor confidence in the company's future development, while also expecting a cash and cash equivalents balance of about $94.3 million as of December 31, 2025.
sensiBel Launches SBM100B Microphone, Delivers Studio-Quality Audio in Compact Form
- Audio Breakthrough: The SBM100B microphone from sensiBel achieves an 80dB signal-to-noise ratio and an acoustic overload point of up to 146dB, delivering studio-quality audio suitable for conferencing and industrial sound detection, significantly enhancing recording flexibility and clarity.
- Technological Innovation: Leveraging optical MEMS core technology, the SBM100B overcomes traditional MEMS microphone limitations by using laser interferometry to detect membrane movement, enabling a wider dynamic range and lower noise floor while maintaining a compact form factor, thus advancing audio technology.
- Convenient Solutions: The AURORA and POLARIS kits connect via USB-C, allowing users to start recording within minutes without soldering or specialized tools, greatly simplifying the design process and enhancing product competitiveness in the market.
- Diverse Applications: The SBM100B is applicable in various scenarios such as video conferencing and spatial audio capture, providing exceptional directionality and high bandwidth to meet the growing market demand, supporting sensiBel's transformation and growth in the audio industry.
Examining Senseonics' Story Following Analyst Adjustments and Product Pipeline Developments
Analyst Adjustments: Senseonics Holdings maintains a fair value of approximately $18.92 per share, with slight adjustments in discount rates and revenue growth expectations reflecting a recalibration rather than a fundamental change in the company's long-term outlook.
Bullish and Bearish Perspectives: TD Cowen remains bullish with a Buy rating despite lowering its price target to $15, while Stifel adopts a more cautious Hold rating with a $9 target, highlighting execution and capital risks as key concerns.
Market Visibility and Listing Changes: Senseonics has been added to the NASDAQ Composite Index and will transfer its primary listing to the Nasdaq Global Select Market in 2025, enhancing its visibility among institutional investors.
Future Growth Projections: The company targets $35 million in global net revenue for 2025, driven by the U.S. rollout of Eversense 365 and a doubling of its patient base, while also executing a reverse stock split to maintain listing compliance.
Senseonics Shares Decline as 2025 Forecast Falls Short of Expectations
Financial Performance: Senseonics Holdings reported Q3 2025 revenue of $8.1M, reflecting nearly 90% year-over-year growth, but set its full-year revenue outlook at $35M, below analyst expectations of $36.3M.
Net Loss and Margins: The company's net loss narrowed by 19% year-over-year to $19.5M, missing consensus estimates, despite cuts to R&D expenses and improved gross margins for its Eversense 365 glucose monitoring devices.
TD Cowen Keeps Buy Rating on Senseonics Holdings, Reduces Price Target to $15
Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.
